Aethlon Medical Net Acquisitions/Divestitures 2012-2026 | AEMD

Aethlon Medical net acquisitions/divestitures from 2012 to 2026. Net acquisitions/divestitures can be defined as the total change in cash resulting from both investments in businesses and sales of businesses or business segments.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Aethlon Medical Annual Net Acquisitions/Divestitures
(Millions of US $)
Sector Industry Market Cap Revenue
Medical Medical - Health Maintenance Organizations $0.005B $0.000B
Aethlon Medical, Inc. is a development stage medical device company focused on expanding the applications of our Hemopurifier (R) platform technology, which is designed to rapidly reduce the presence of infectious viruses and other toxins from human blood. In this regard, its core focus is the development of therapeutic devices that treat acute viral conditions, chronic viral diseases and pathogens targeted as potential biological warfare agents. The Hemopurifier(R) combines the established scientific principles of affinity chromatography and hemodialysis as a means to mimic the immune system's response of clearing viruses and toxins from the blood before cell and organ infection can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent virus and toxins from infecting unaffected tissues and cells. The company has completed pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C, and have completed human safety trials on Hepatitis-C infected patients in India.
Stock Name Country Market Cap PE Ratio
UnitedHealth Group (UNH) United States $336.787B 20.13
Cigna Group (CI) United States $72.930B 8.77
Humana (HUM) United States $46.173B 22.36
Centene (CNC) United States $33.147B 12.93
Molina Healthcare (MOH) United States $10.706B 69.52
Select Medical Holdings (SEM) United States $2.046B 15.43
Joint (JYNT) United States $0.119B 56.20